Major and minor amputation rates and critical lower limb ischemia: Epidemiological data from western Tuscany;Tassi di amputazione maggiore e minore ed ischemia critica degli arti inferiori: Dati epidemiologici dalla Toscana occidentale

Italian Heart Journal Supplement

Volumn 5, Issue 10, 2004, Pages 794-805

  Melillo, Elio ^a   Nuti, Marco ^a   Bongiorni, Lorenzo ^b   Golgini, Elisabetta ^b   Balbarini, Alberto ^a  

^a CISANELLO HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Critical limb ischemia; Diabetes mellitus; Epidemiology; Mortality

Indexed keywords

ADOLESCENT; ADULT; AGED; AMPUTATION; ARTERIOSCLEROSIS; ARTICLE; CHI SQUARE DISTRIBUTION; CHILD; COHORT ANALYSIS; COMPARATIVE STUDY; CRITICAL ILLNESS; DIABETIC ANGIOPATHY; FEMALE; HUMAN; ISCHEMIA; ITALY; LEG; MALE; MIDDLE AGED; MORTALITY; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICS; VASCULARIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMPUTATION; ARTERIOSCLEROSIS; CHI-SQUARE DISTRIBUTION; CHILD; COHORT STUDIES; CRITICAL ILLNESS; DATA INTERPRETATION, STATISTICAL; DIABETIC ANGIOPATHIES; FEMALE; HOSPITAL MORTALITY; HUMANS; ISCHEMIA; ITALY; LEG; MALE; MIDDLE AGED; RISK FACTORS;

EID: 16644396149     PISSN: 15903796     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Catalano M. Epidemiology of critical limb ischaemia: north Italian data. Eur J Med 1993; 2: 11-4. (Pubitemid 23042545)
2. Dormandy J, Heeck L, Vig S. Predicting which patients will develop chronic critical leg ischemia. Semin Vasc Surg 1999; 12: 138-41. (Pubitemid 29259201)
3. Dormandy JA, Rutherford RB. Management of peripheral arterial disease. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000; 31 (Part 2): S1-S296.
4. Dati demografici ISTAT sulla popolazione italiana 2002. http://demo.istat.it/pop2003/index.html
5. Melillo E, Nuti M, Buttitta F, et al. Salvataggio d'arto farmacologico mediante iloprost nella ischemia critica degli arti inferiori non rivascolarizzabile: conferme e modifiche della nostra condotta terapeutica negli ultimi otto anni. Minerva Cardioangiol 2003; 51 (Suppl 1 al n 6): 253-5.
6. http://www.regione.toscana.it
7. Hughson WG, Mann JI, Garrod A. Intermittent claudication: prevalence and risk factors. BMJ 1978; 1: 1379-81. (Pubitemid 8334003)
8. Reunanen A, Takkunen H, Aromaa A. Prevalence of intermittent claudication and its effect on mortality. Acta Med Scand 1982; 211: 249-56. (Pubitemid 12102543)
9. De Backer IG, Kornitzer M, Sobolski J, Denolin H. Intermittent claudication: epidemiology and natural history. Acta Cardiol 1979; 34: 1115-24. (Pubitemid 9209918)
10. Smith WCS, Woodward M, Tunstall-Pedoe H. Intermittent claudication in Scotland. In: Fowkes FG, ed. Epidemiology of peripheral vascular disease. London: Springer-Verlag, 1991: 109-15.
11. Novo S, Avellone G, Di Garbo V, et al. Prevalence and risk factors in patients with peripheral arterial disease: a clinical and epidemiological evaluation. Int Angiol 1992; 11: 218-29.
12. Fowkes FGR, Housley E, Cawood EH, et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1992; 20: 384-92.
13. Widmer LK, Greensher A, Kannel WB. Occlusion of peripheral arteries: a study of 6400 working subjects. Circulation 1964; 30: 836-42.
14. Gofin R, Kark JD, Friedlander Y, et al. Peripheral vascular disease in a middle-aged population sample. The Jerusalem Lipid Research Clinic Prevalence Study. Isr J Med Sci 1987; 23: 157-67. (Pubitemid 17077334)
15. Kannel WB, Skinner JJ Jr, Schwartz MJ, Shurtleff D. Intermittent claudication: incidence in the Framingham study. Circulation 1970; 41: 875-83.
16. Bowlin SJ, Medalie JH, Flocke SA, et al. Epidemiology of intermittent claudication in middle-aged men. Am J Epidemiol 1994; 140: 418-30.
17. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985; 71: 510-5. (Pubitemid 15133809)
18. Stoffers HE, Rinkens PE, Kester AD, et al. The prevalence of asymptomatic and unrecognised peripheral arterial occlusive disease. Int J Epidemiol 1996; 25: 282-90.
19. Meijer WT, Hoes AW, Rutgers DM, Bots ML, Hofman A, Grobbee DE. Peripheral arterial disease in the elderly: the Rotterdam study. Arterioscler Thromb Vasc Biol 1998; 18: 185-92. (Pubitemid 28277594)
20. Widmer LK, Da Silva A. Historical perspectives and the Basle study. In: Fowkes FG, ed. Epidemiology of peripheral vascular disease. London: Springer-Verlag, 1991: 69-83.
21. Brevetti G, Oliva G, Silvestro A, et al, for the Peripheral Arteriopathy and Cardiovascular Events (PACE) Study Group. Prevalence, risk factors and cardiovascular comorbidity of symptomatic peripheral arterial disease in Italy. Atherosclerosis 2004; 175: 131-8.
22. Heliovaara M, Karvonen MJ, Vilhunen R, Punsar S. Smoking, carbon monoxide, and atherosclerotic diseases. BMJ 1978; 1: 268-70. (Pubitemid 8316104)
23. Diehm C, Schuster A, Allenberg JR, et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis 2004; 172: 95-105. (Pubitemid 38058606)
24. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral artery disease. The San Luis Valley Diabetes Study. Circulation 1995; 91: 1472-9.
25. Dormandy JA, Murray GD. The fate of the claudicant: a prospective study of 1969 claudicants. Eur J Vasc Surg 1991; 5: 131-3.
26. Dolan NC, Liu K, Criqui MH, et al. Peripheral artery disease, diabetes, and reduced lower extremity functioning. Diabetes Care 2002; 25: 113-20.
27. Matzke S, Lepantalo M. Claudication does not always precede critical leg ischemia. Vasc Med 2001; 6: 77-80. (Pubitemid 32791507)
28. Dormandy JA, Belcher G, Broos P, et al. Prospective study of 713 below-knee amputations for ischaemia and the effect of a prostacyclin analogue on healing. Hawaii Study Group. Br J Surg 1994; 81: 33-7. (Pubitemid 24048927)
29. The Vascular Surgical Society of Great Britain and Ireland. Critical limb ischaemia: management and outcome. Report of a national survey. Eur J Vasc Endovasc Surg 1995; 10: 108-13.
30. Ebskov LB, Schoeder TV, Holstein PE. Epidemiology of leg amputation: the influence of vascular surgery. Br J Surg 1994; 81: 1600-3.
31. Norgren L. Definition, incidence and epidemiology. In: Dormandy JA, Stock G, eds. Critical leg ischaemia: its pathophysiology and management. Berlin: Springer-Verlag, 1990: 7-13.
32. Kacy SS, Wolma FJ, Flye MW. Factors affecting the results of below-knee amputation in patients with and without diabetes. Surg Gynaecol Obstet 1982; 155: 513-8.
33. Dormandy JA, Ray S. The natural history of peripheral arterial disease. In: Tooke JE, Lowe GD, eds. A textbook of vascular medicine. London: Arnold, 1996: 162-75.
34. Kok FJ, Kromhout D. Atherosclerosis: epidemiological studies on the health effects of a Mediterranean diet. Eur J Nutr 2004; 43 (Suppl 1): 12-5.
35. Martinez-Gonzalez MA, Sanchez-Villegas A. The emerging role of Mediterranean diets in cardiovascular epidemiology: monounsaturated fats, olive oil, red wine or the whole pattern? Eur J Epidemiol 2004; 19: 9-13.
36. Ventura P, Bini A, Panini R, et al. Red wine consumption prevents vascular oxidative stress induced by a high-fat meal in healthy volunteers. Int J Vitam Nutr Res 2004; 74: 137-43. (Pubitemid 38788780)
37. Casani L, Segales E, Vilahur G, et al. Moderate daily intake of red wine inhibits mural thrombosis and monocyte tissue factor expression in an experimental porcine model. Circulation 2004; 110: 460-5. (Pubitemid 38993857)
38. Estruch R, Sacanella E, Badia E, et al. Different effects of red wine and gin consumption on inflammatory biomarkers atherosclerosis: a prospective randomized crossover trial. Effects of wine on inflammatory markers. Atherosclerosis 2004; 175: 117-23.
39. Menotti A, Lanti M, Puddu PE, Kromhout D. Coronary heart disease incidence in northern and southern European populations: a reanalysis of the seven countries study for a European coronary risk chart. Heart 2000; 84: 238-44.
40. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, II: maintenance of vascular grafts or arterial patency by antiplatelet therapy. BMJ 1994; 308: 159-68.
41. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
42. Patrono C, Bachmann F, Baigent C, et al, for the European Society of Cardiology. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur Heart J 2004; 25: 166-81.
43. Aronow WS, Nayak D, Woodworth S, Ahn C. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol 2003; 92: 711-2. (Pubitemid 37103026)
44. Schillinger M, Exner M, Mlekusch W, et al. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J 2004; 25: 742-8. (Pubitemid 38647934)
45. Ostergren J, Sleight P, Yusuf S, et al, for the HOPE Study Investigators. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004; 25: 17-24.
46. Warner GT, Perry CM. Ramipril: a review of its use in the prevention of cardiovascular outcomes. Drugs 2002; 62: 1381-405.
47. Wolfe JH. Defining the outcome of critical ischaemia: a one year prospective study. (abstr) Br J Surg 1986; 73: 321.
48. The ICAI Group (Gruppo di Studio dell'Ischemia Cronica Critica degli Arti Inferiori). Long-term mortality and its predictors in patients with critical leg ischaemia. Eur J Vasc Endovasc Surg 1997; 14: 91-5.
49. Rush DS, Huston CC, Bivins BA, Hyde GL. Operative and late mortality rates of above-knee and below-knee amputations. Am Surg 1981; 47: 36-9.
50. Jamieson MG, Ruckley CV. Amputation for peripheral vascular disease in a general surgical unit. J R Coll Surg Edinb 1983; 28: 46-50. (Pubitemid 13130613)
51. Valentine RJ, Myers SI, Inman MH, et al. Late outcome of amputees with premature atherosclerosis. Surgery 1996; 119: 487-93.
52. Kinh RB, Warren FW, Beebe GW. The "geriatric" amputee. Ann Surg 1972; 176: 305-14.
53. Liedberg E, Persson BM. Age, diabetes and smoking in lower limb amputation for arterial occlusive disease. Acta Orthop Scand 1983; 54: 383-8. (Pubitemid 13053487)
54. Eichoff JH, Hansen HJ, Lorentzen JE. The effect of arterial reconstruction on lower limb amputation rate. Acta Chir Scand 1980; 502: 181-7.
55. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979; 241: 2035-8.
56. Kannel WB. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. J Cardiovasc Risk 1994; 1: 333-9.
57. Hansson J. The leg amputee: a clinical follow-up study. Acta Orthop Scand 1964; 69 (Suppl 69): 1-104.
58. Pell JP, Fowkes FG. Risk factors for critical limb ischaemia. Epidemiol Update 1997; 2: 19-25.
59. Varty K, Nydahl S, Butterworth P, et al. Changes in the management of critical limb ischaemia. Br J Surg 1996; 83: 953-6. (Pubitemid 26228214)
60. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double-blind placebo-controlled study. UK Severe Limb Ischaemia Study Group. Eur J Vasc Surg 1991; 5: 511-6.
61. Norgren L, Alwmark A, Angqvist KA, et al. A stable prostacyclin analogue (iloprost) in the treatment of ischaemic ulcers of the lower limb: a Scandinavian-Polish placebo controlled randomised multicentre study. Eur J Vasc Surg 1990; 4: 463-7. (Pubitemid 20347988)
62. Loosemore TM, Chalmers TC, Dormandy JA. A metaanalysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease. Intern Angiol 1994; 13: 133-42.
63. Trubestein G, Diehm C, Gruss JD, Horsch S. Prostaglandin E1 in chronic arterial disease: a multicenter study. Vasa Suppl 1987; 17: 39-43. (Pubitemid 17019329)
64. Brock FE, Abri O, Baitsch G, et al. Iloprost in the treatment of ischemic tissue lesions in diabetics: results of a placebo-controlled multicenter study with a stable prostacyclin derivative. Schweitz Med Wochenschr 1990; 120: 1477-82.
65. Altstaedt HO, Berzewski B, Breddin HK, et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukot Essent Fatty Acids 1993; 49: 573-8. (Pubitemid 23236517)
66. GISAP Study. Evaluation of a conservative treatment with iloprost in severe peripheral occlusive arterial disease (POAD). Int Angiol 1994; 13: 70-4.
67. Melillo E, Iabichella L, Berchiolli R, et al. Transcutaneous oxygen and carbon dioxide during treatment of critical limb ischemia with iloprost, a prostacyclin derivative. Int J Microcirc Clin Exp 1995; 15: 60-4.
68. Staben P, Albring M. Treatment of patients with peripheral arterial occlusive disease Fontaine stage III and IV with intravenous iloprost: an open study in 900 patients. Prostaglandins Leukot Essent Fatty Acids 1996; 54: 327-33. (Pubitemid 26232812)
69. Beischer W, Dembski JC, Gruss JD, et al, for the DAWID Study Group. Low-dose iloprost infusions compared to the standard dose in patients with peripheral arterial occlusive disease Fontaine stage IV. Vasa 1998; 27: 15-9.
70. Duthois S, Cailleux N, Levesque H. Tolerance and therapeutic results of iloprost in obliterative arteriopathy in lower limbs at the severe chronic ischemia stage. A retrospective study of 29 consecutive cases. J Mal Vasc 2000; 25: 17-26.
71. Duthois S, Cailleux N, Benosman B, Levesque H. Tolerance of Iloprost and results of treatment of chronic severe lower limb ischaemia in diabetic patients. A retrospective study of 64 consecutive cases. Diabetes Metab 2003; 29: 36-43.